Molly M. Hood

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Bryan D. Smith, Michael D. Kaufman, Wei-Ping Lu et al. · Cancer Cell · 2019 · 270 citations

Pdgfra Variants, Oncogenic Agent, Medicine +9

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036

Wayne W. Chan, Scott Wise, Michael D. Kaufman et al. · Cancer Cell · 2011 · 204 citations · Full text

Switch-control Inhibitor Dcc-2036, Signal Transduction, Signaling Pathway +9

The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors

Allison S. Harney, George S. Karagiannis, Jeanine Pignatelli et al. · Molecular Cancer Therapeutics · 2017 · 162 citations · Full text

A Novel Combination of Vitamin C, Curcumin and Glycyrrhizic Acid Potentially Regulates Immune and Inflammatory Response Associated with Coronavirus Infections: A Perspective from System Biology Analysis

Liang Chen, Chun Hu, Molly M. Hood et al. · Nutrients · 2020 · 129 citations · Full text

Microbial Pathogens, Immunology, Viral Pathogenesis +21

Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against <i>BRAF</i> or <i>RAS</i> Mutant Tumor Cells

James R. Henry, Michael D. Kaufman, Sheng-Bin Peng et al. · Journal of Medicinal Chemistry · 2015 · 84 citations · Full text

Kinase Inhibitors, Pharmaceutical Chemistry, Tumor Biology +20